General cardiovascu- lar risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743 53. S2.2-56. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611 9. S2.2-57. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243 51; 4p following 2251. S2.2-58. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999 3058. S2.2-59. JBS3 Board. Joint British Societies consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100 suppl 2 2014:ii1 67. S2.2-60. Anderson TJ, Gr goire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipid- emia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32:1263 82. S2.2-61. Downs JR, O Malley PG. Management of dyslipidemia for cardiovas- cular disease risk reduction: synopsis of the 2014 US Department of Veterans Affairs and US Department of Defense clinical practice guideline. Ann Intern Med. 2015;163:291 7. S2.2-62. Bibbins-Domingo KUS Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal can- cer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836 45. S2.2-63. US Preventive Services Task Force Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular dis- ease in adults: US Preventive Services Task Force Re64commendation Statement. JAMA. 2016;316:1997 2007. S2.2-64. Karmali KN, Goff DC Jr, Ning H, et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for athero- sclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959 68. S2.2-65. 